BACKGROUND: Viral tropism influences the natural history of human immunodeficiency type 1 (HIV-1) disease: X4 viruses are associated with faster decreases in CD4 cell count. There is scarce information about the influence of viral tropism on treatment outcomes. METHODS: Baseline plasma samples from patients recruited to the ArTEN (Atazanavir/ritnoavir vs. Nevirapine on a background of Tenofovir and Emtricitabine) trial were retrospectively tested for HIV-1 tropism using the genotypic tool geno2pheno(FPR=5.75%). ArTEN compared nevirapine with atazanavir-ritonavir, both along with tenofovir-emtricitabine, in drug-naïve patients. RESULTS:Of 569 ArTEN patients, 428 completed 48 weeks of therapy; 282 of these receivednevirapine and 146 of these received atazanavir-ritonavir. Overall, non-B subtypes of HIV-1 were recognized in 96 patients (22%) and X4 viruses were detected in 55 patients (14%). At baseline, patients with X4 viruses had higher plasma HIV RNA levels (5.4 vs 5.2 log copies/mL, respectively; P = .044) and lower CD4 cell counts (145 vs 188 cells/μL, respectively; P < .001) than those with R5 strains. At week 48, virologic responses were lower in patients with X4 viruses than in patients with R5 viruses (77% vs 92%, respectively; P = .009). Multivariate analysis confirmed HIV-1 tropism as an independent predictor of virologic response at week 24 (P = .012). This association was extended to week 48 (P = .007) in clade B viruses. Conversely, CD4 cell count recovery was not influenced by baseline HIV-1 tropism. CONCLUSIONS: HIV-1 tropism is an independent predictor of virologic response to first-line antiretroviral therapy. In contrast, it does not seem to influence CD4 cell count recovery. CLINICAL TRIALS REGISTRATION: NCT00389207.
RCT Entities:
BACKGROUND:Viral tropism influences the natural history of humanimmunodeficiency type 1 (HIV-1) disease: X4 viruses are associated with faster decreases in CD4 cell count. There is scarce information about the influence of viral tropism on treatment outcomes. METHODS: Baseline plasma samples from patients recruited to the ArTEN (Atazanavir/ritnoavir vs. Nevirapine on a background of Tenofovir and Emtricitabine) trial were retrospectively tested for HIV-1 tropism using the genotypic tool geno2pheno(FPR=5.75%). ArTEN compared nevirapine with atazanavir-ritonavir, both along with tenofovir-emtricitabine, in drug-naïve patients. RESULTS: Of 569 ArTENpatients, 428 completed 48 weeks of therapy; 282 of these received nevirapine and 146 of these received atazanavir-ritonavir. Overall, non-B subtypes of HIV-1 were recognized in 96 patients (22%) and X4 viruses were detected in 55 patients (14%). At baseline, patients with X4 viruses had higher plasma HIV RNA levels (5.4 vs 5.2 log copies/mL, respectively; P = .044) and lower CD4 cell counts (145 vs 188 cells/μL, respectively; P < .001) than those with R5 strains. At week 48, virologic responses were lower in patients with X4 viruses than in patients with R5 viruses (77% vs 92%, respectively; P = .009). Multivariate analysis confirmed HIV-1 tropism as an independent predictor of virologic response at week 24 (P = .012). This association was extended to week 48 (P = .007) in clade B viruses. Conversely, CD4 cell count recovery was not influenced by baseline HIV-1 tropism. CONCLUSIONS:HIV-1 tropism is an independent predictor of virologic response to first-line antiretroviral therapy. In contrast, it does not seem to influence CD4 cell count recovery. CLINICAL TRIALS REGISTRATION: NCT00389207.
Authors: Zabrina L Brumme; Winnie W Y Dong; Benita Yip; Brian Wynhoven; Noah G Hoffman; Ronald Swanstrom; Mark A Jensen; James I Mullins; Robert S Hogg; Julio S G Montaner; P Richard Harrigan Journal: AIDS Date: 2004-03-05 Impact factor: 4.177
Authors: Peter W Hunt; P Richard Harrigan; Wei Huang; Michael Bates; David W Williamson; Joseph M McCune; Richard W Price; Serena S Spudich; Harry Lampiris; Rebecca Hoh; Teri Leigler; Jeffrey N Martin; Steven G Deeks Journal: J Infect Dis Date: 2006-08-29 Impact factor: 5.226
Authors: Vicente Soriano; Keikawus Arastéh; Horacio Migrone; Thomas Lutz; Milos Opravil; Jaime Andrade-Villanueva; Francisco Antunes; Giovanni Di Perri; Daniel Podzamczer; Steve Taylor; Pere Domingo; Holger Gellermann; Lothar de Rossi Journal: Antivir Ther Date: 2011
Authors: Verónica Briz; Eva Poveda; María del Mar González; Luz Martín-Carbonero; Rocío González-González; Vincent Soriano Journal: J Antimicrob Chemother Date: 2007-12-06 Impact factor: 5.790
Authors: Eva Poveda; Eduardo Seclén; María del Mar González; Federico García; Natalia Chueca; Antonio Aguilera; Jose Javier Rodríguez; Juan González-Lahoz; Vincent Soriano Journal: J Antimicrob Chemother Date: 2009-03-03 Impact factor: 5.790
Authors: Eric S Daar; Karen L Kesler; Christos J Petropoulos; Wei Huang; Michael Bates; Alice E Lail; Eoin P Coakley; Edward D Gomperts; Sharyne M Donfield Journal: Clin Infect Dis Date: 2007-07-20 Impact factor: 9.079
Authors: Barbara Weiser; Sean Philpott; Thomas Klimkait; Harold Burger; Christina Kitchen; Philippe Bürgisser; Meri Gorgievski; Luc Perrin; Jean-Claude Piffaretti; Bruno Ledergerber Journal: AIDS Date: 2008-02-19 Impact factor: 4.177
Authors: Matthew Bidwell Goetz; Robert Leduc; Jay R Kostman; Ann M Labriola; Yolanda Lie; Jodi Weidler; Eoin Coakley; Michael Bates; Roberta Luskin-Hawk Journal: J Acquir Immune Defic Syndr Date: 2009-03-01 Impact factor: 3.731
Authors: Esther F Gijsbers; Ard van Sighem; Agnes M Harskamp; Matthijs R A Welkers; Frank de Wolf; Kees Brinkman; Jan M Prins; Hanneke Schuitemaker; Angélique B van 't Wout; Neeltje A Kootstra Journal: PLoS One Date: 2013-10-01 Impact factor: 3.240